Founded in 2013 in California, Pharmapace provides biometric services for all stages of clinical trials such as clinical and statistical programming, data management and biostatistics.
Post acquisition, Pharmapace will become a wholly-owned subsidiary of WuXi Clinical, the clinical contract research organisation arm of WuXi AppTec.
The acquisition will help WuXi expand its biometrics capabilities in the United States and Europe.
“This acquisition further enhances WuXi Clinical’s drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost-effectively provide customers seamless biometrics services globally,” said WuXi AppTec co-CEO Edward Hu.
Pharmapace will continue its focus on growing its core biometric competencies and integrate with WuXi Clinical’s other clinical development services.
With the two organisations teaming up, WuXi Clinical claims it has over 850 employees in China and the US and can provide a full range of clinical development services to its customers.
China is a leading clinical trial market in Asia and with the recent regulatory changes made by the China Food and Drug Administration, clinical trial institutions and investigators are expected to get more support for clinical trial developments.